A comprehensive approach utilizing <i>in silico</i>, <i>in-vitro</i>, and <i>in-vivo</i> methodologies reveals that PNN targets key molecular pathways implicated in MS, including the GDNF/GFRA1/RET/AKT/ERK1/2/GSK3-Beta signaling cascade. This evidence concerns the gene GFRA1 and myeloid sarcoma.